Development of prevention for cisplatin-induced ototoxicity based on analysis of clinical big data

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06689
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Osaka University
• Principal Investigator: Ikemura Kenji 大阪大学, 医学部附属病院, 講師 (70513935)
• Co-Investigator(Kenkyū-buntansha): 奥田 真弘 大阪大学, 医学部附属病院, 教授 (70252426) ; 西村 有平 三重大学, 医学系研究科, 教授 (30303720)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: シスプラチン / 難聴 / 有機カチオントランスポータ２ / プロトンポンプ阻害薬

Outline of Final Research Achievements

Adverse event database analysis demonstrated that co-administration of proton pump inhibitors (PPIs) ameliorated cisplatin (CDDP)-induced ototoxicity. Moreover, co-treatment of lansoprazole, which is one of PPIs, significantly suppressed the hair cell damages in zebrafish treated with CDDP. Retrospective clinical study indicated that the incidence rate of ototoxicity was significantly lower in patients with LPZ compared to those without LPZ. These findings suggested that PPIs should ameliorated CDDP-induced ototoxicity. Therefore, the present findings provided important information for the establishment of novel protective approaches to minimize CDDP-induced ototoxicity.

Free Research Field

医療薬学

Academic Significance and Societal Importance of the Research Achievements

本研究成果は、長年にわたり回避することが困難であったシスプラチンの難聴に対する支持療法構築に向けた有用な新知見であると考えられる。さらに、臨床への還元を意識し、安全性が認められている既存薬から新たな使用方法を見つけ出すドラッグリポジショニングという研究概念も兼ね揃えており、社会的意義の高い研究である。